Gunilla Osswald, BioArctic 🇸🇪 | Leqembi, Alzheimer’s disease | E26 episode artwork

EPISODE · Dec 9, 2024 · 54 MIN

Gunilla Osswald, BioArctic 🇸🇪 | Leqembi, Alzheimer’s disease | E26

from Flot.bio x Philip Hemme · host Flot.bio

We’re at BIO-Europe in Stockholm 🇸🇪 with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer's.We talked about the science and business behind Leqembi. We also talked about the Alzheimer’s field at large and transitioning from big pharma to biotech. — — —Thank you to today’s sponsor, Turbine, who is organizing a free Techbio event at JPM25 and is inviting you to join. Click the link to RSVP and secure one of the limited spots: https://www.turbine.ai/jpm25-event-registration— — —⭐️ ABOUT THE SPEAKERGunilla joined BioArctic in 2013 after many successful years in executive positions at Astra/AstraZeneca, including Vice President for the product portfolio of neurodegenerative diseases. Since joining BioArctic, the largest Swedish biotech, Leqembi, one of the only successful drugs for Alzheimer’s was approved. This was an invention of BioArctic that Eisai and Biogen have commercialized. This is a particularly impressive feat considering 98% of Alzheimer’s drugs fail. 🔗 LINKS MENTIONED- - The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more: https://www.biotechtv.com/post/bioarctic-gunilla-osswald-september-21-2024- Roche sees rapid amyloid clearing in Alzheimer's study, adjusts protocol after patient death: https://www.fiercebiotech.com/biotech/roche-sees-rapid-amyloid-clearing-early-alzheimers-study- Edwin Moses | How to build large biotech platforms | E13: https://flot.bio/episode/edwin-moses-biotech-platforms/- The 25 Most Valuable Biotech Companies in Europe in 2025: https://flot.bio/most-valuable-biotech-companies-europe-2025/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/gunilla-osswald-bioarctic-alzheimers/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.⏰ TIMESTAMPS [00:00:00] Intro[00:02:24] Leqembi and BioArctic [00:10:40] Side effects of Leqembi for Alzheimer's treatment[00:17:03] Passing the blood-brain barrier for better Alzheimer's treatments[00:21:00] Market access for Leqembi in Europe[00:27:03] Gunilla Osswald's commitment to patients[00:31:55] Leaving AstraZeneca, transitioning to biotech[00:38:42] Unique culture at BioArctic[00:42:26] Alzheimer's field in Europe and at large[00:48:20] Quickfire[00:53:42] Thanks for listening

We’re at BIO-Europe in Stockholm 🇸🇪 with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer's.We talked about the science and business behind Leqembi. We also talked about the Alzheimer’s field at large and transitioning from big pharma to biotech. — — —Thank you to today’s sponsor, Turbine, who is organizing a free Techbio event at JPM25 and is inviting you to join. Click the link to RSVP and secure one of the limited spots: https://www.turbine.ai/jpm25-event-registration— — —⭐️ ABOUT THE SPEAKERGunilla joined BioArctic in 2013 after many successful years in executive positions at Astra/AstraZeneca, including Vice President for the product portfolio of neurodegenerative diseases. Since joining BioArctic, the largest Swedish biotech, Leqembi, one of the only successful drugs for Alzheimer’s was approved. This was an invention of BioArctic that Eisai and Biogen have commercialized. This is a particularly impressive feat considering 98% of Alzheimer’s drugs fail. 🔗 LINKS MENTIONED- - The CEO of BioArctic talks Leqembi and what's next in Alzheimer's, Parkinson's, ALS, and more: https://www.biotechtv.com/post/bioarctic-gunilla-osswald-september-21-2024- Roche sees rapid amyloid clearing in Alzheimer's study, adjusts protocol after patient death: https://www.fiercebiotech.com/biotech/roche-sees-rapid-amyloid-clearing-early-alzheimers-study- Edwin Moses | How to build large biotech platforms | E13: https://flot.bio/episode/edwin-moses-biotech-platforms/- The 25 Most Valuable Biotech Companies in Europe in 2025: https://flot.bio/most-valuable-biotech-companies-europe-2025/📜 TRANSCRIPTRead the full transcript here: https://flot.bio/episode/gunilla-osswald-bioarctic-alzheimers/💸 DONATEWe welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme⭐️ SPONSORSHIPReady to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts!🫶 FOLLOW US- Newsletter: http://eepurl.com/h_fnmH- LinkedIn: https://www.linkedin.com/company/flot-bio/- X (Twitter): https://x.com/FlotBio🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.🎙️ ABOUT FLOT.BIOFlot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.⏰ TIMESTAMPS [00:00:00] Intro[00:02:24] Leqembi and BioArctic [00:10:40] Side effects of Leqembi for Alzheimer's treatment[00:17:03] Passing the blood-brain barrier for better Alzheimer's treatments[00:21:00] Market access for Leqembi in Europe[00:27:03] Gunilla Osswald's commitment to patients[00:31:55] Leaving AstraZeneca, transitioning to biotech[00:38:42] Unique culture at BioArctic[00:42:26] Alzheimer's field in Europe and at large[00:48:20] Quickfire[00:53:42] Thanks for listening

NOW PLAYING

Gunilla Osswald, BioArctic 🇸🇪 | Leqembi, Alzheimer’s disease | E26

0:00 54:25

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Flot.bio x Philip Hemme?

This episode is 54 minutes long.

When was this Flot.bio x Philip Hemme episode published?

This episode was published on December 9, 2024.

What is this episode about?

We’re at BIO-Europe in Stockholm 🇸🇪 with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer's.We talked about the science and business behind Leqembi. We also talked about the Alzheimer’s...

Can I download this Flot.bio x Philip Hemme episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!